Examining Chemotherapy-Related Cognitive Changes in Colorectal Cancer Patients: A Feasibility Trial by Dwek, M. R. et al.
Dwek, M. R., Rixon, L., Simon, A., Hurt, C. S. & Newman, S. P. (2016). Examining Chemotherapy-
Related Cognitive Changes in Colorectal Cancer Patients: A Feasibility Trial. Cancer Open Access, 
1(1), pp. 5-8. 
City Research Online
Original citation: Dwek, M. R., Rixon, L., Simon, A., Hurt, C. S. & Newman, S. P. (2016). 
Examining Chemotherapy-Related Cognitive Changes in Colorectal Cancer Patients: A Feasibility 
Trial. Cancer Open Access, 1(1), pp. 5-8. 
Permanent City Research Online URL: http://openaccess.city.ac.uk/15696/
 
Copyright & reuse
City University London has developed City Research Online so that its users may access the 
research outputs of City University London's staff. Copyright © and Moral Rights for this paper are 
retained by the individual author(s) and/ or other copyright holders.  All material in City Research 
Online is checked for eligibility for copyright before being made available in the live archive. URLs 
from City Research Online may be freely distributed and linked to from other web pages. 
Versions of research
The version in City Research Online may differ from the final published version. Users are advised 
to check the Permanent City Research Online URL above for the status of the paper.
Enquiries
If you have any enquiries about any aspect of City Research Online, or if you wish to make contact 
with the author(s) of this paper, please email the team at publications@city.ac.uk.
Cancer Open Access
Research Article
Volume 1 • Issue 1 | Page 5 of 8
Examining Chemotherapy-Related Cognitive Changes in Colorectal 
Cancer Patients: A Feasibility Trial
Marie-Rose Dwek1, Lorna Rixon1, Alice Simon2, Catherine Hurt1, Stanton Newman1*
Abstract
Introduction: Research suggests that chemotherapy may be related to decline in 
patients’ cognitive functions. 
Objectives: To assess the feasibility and acceptability of a multi-site study designed 
to examine the nature and extent of chemotherapy-related cognitive changes in 
colorectal cancer patients. 
Method: Data was collected over 8 months using objective and self-reported 
measures of cognitive functioning and self-reported quality of life, fatigue and mood 
questionnaires. The assessment battery was administered pre- and mid-chemotherapy 
treatment to a consecutive sample of colorectal cancer patients across three London-
based NHS Trusts. Participants included patients who had undergone colorectal surgery 
and were scheduled to have adjuvant chemotherapy treatment, or no further cancer 
treatment. 
Main outcome measures: Recruitment procedures, rate of recruitment, suitability 
of exclusion/inclusion criteria, acceptability of data collection procedures and the battery, 
and attrition rates.
Results: From 1 April 2014 to 1 December 2014, 42 eligible participants were invited 
to take part in the trial. Of the 17 that completed pre-chemotherapy assessments, only 1 
withdrew at follow-up due to reasons of ill health from disease recurrence. All participants 
completed the entire battery and indicated that they found the trial acceptable.
Conclusions: What went wrong: Strained researcher resources; loss of eligible 
participants to competing studies, restrictive upper age limit. 
Possible solutions: Removal of upper age limit, an increased dedicated research 
team to increase rate of recruitment.
The large multi-site study is feasible with suggested amendments and is acceptable 
to patients and medical teams. Acceptability of trial to medical teams is further evidenced 
by requests of collaboration from two additional London based NHS Trusts. 
Lessons learned: This feasibility trial provides evidence to other researchers 
designing similar studies in this area of an acceptable design and the need for appropriate 
funding for resources to recruit large enough consecutive samples of patients with solid 
tumour cancers
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Introduction
Research suggests that chemotherapy may be related to a decline in cognitive 
functions such as memory and atention in some solid tumour cancer patients [1-4]. 
However, the presence, extent and course of any cognitive decline and whether or not 
it causes observable di culties for patients remain unclear. 
he majority of research studies to date have explored cognitive function in cancer 
patients ater treatment has been completed [5]. Few studies have measured patients’ 
cognitive function prior to the commencement of chemotherapy treatment and hence 
these studies do not have any baseline. Measuring cognitive function both before 
and ater chemotherapy would make it possible to identify changes occurring during 
treatment and the duration of such treatment related changes. 
An additional limitation of existing studies is that they have oten lacked a 
comparison group (e.g. cancer patients who have not required chemotherapy) against 
which to compare cognitive function scores. Furthermore, the majority of cognitive 
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research to date has focussed on female breast cancer patients. his 
has precluded an exploration of gender diferences in relation to 
cognitive decline.
his study examines the feasibility of a protocol designed to 
examine the nature and extent of chemotherapy related cognitive 
changes in colorectal cancer (“CRC”) patients (the “Protocol”) 
[6]. Given the proposed scale of the study, it was considered 
appropriate to irst conduct a feasibility trial (the “Trial”). It is 
good practice and important for research to carry out this type of 
feasibility trial prior to a full study [7]. he Trial would determine 
the resources required, whether the Protocol could be implemented 
as designed, or whether any alterations were necessary. 
Objectives
Bowen et al [8] suggested eight general areas of focus that 
may be addressed by feasibility studies for proposed interventions. 
his was narrowed to four areas, as the Trial did not involve an 
intervention. (See Table 1, which deines how the areas of focus 
correspond to the Trial objectives). 
he primary objectives of this Trial were to evaluate: 
Recruitment procedures: In order to assess the maximum 
number of eligible participants, the most eicient procedures for 
recruitment were examined so as to establish and conirm the: 
a)  Extent to which the suggested recruitment procedures could 
be carried out as proposed
b)  Similarities/diferences in recruitment procedures between the 
three collaborating London based NHS Trusts (the ‘Trusts’)
c)  Extent to which the clinical teams were supportive of the Trial
d)  Ease of identifying eligible participants 
e)  Number of eligible participants per Trust.
Participant numbers: A critical issue was to examine the patient 
low as determined by the consent rate of eligible participants 
entering this Trial in order to [9-11]: 
a) Determine the time necessary to recruit a suicient sample
b) Make projections of the funding and resources needed to 
execute an appropriately powered multi-site study
c) Assess the suitability of inclusion/exclusion criteria.
Methodology/testing of data collection procedures and 
assessments: he piloting and assessing acceptability of the 
proposed technique of data collection [11] according to the 
Protocol, was important, as each participant was required 
to undergo a series of neuropsychological assessments and 
questionnaires (the “Batery”). 
Atrition rates: Similar research in breast cancer treatment 
suggests that atrition rates in longitudinal cohort studies range 
from 10% to 33% [12-15]. he extent to which these data would 
be generalisable to the proposed population who difered in 
age, gender, cancer type and course of treatment needed to be 
determined. 
Ethical Approval
Ethical approval was obtained from the NHS Health Research 
Authority – NRES Commitee South-West Cornwall & Plymouth 
in August 2013. As part of the approval process it was also necessary 
to obtain a patient’s perspective and view of the proposed Trial. 
herefore prior to commencing the Trial an advertisement was 
posted on the Macmillan’s Cancer Support online community 
noticeboard (htp://community.macmillan.org.uk/volunteering/
noticeboard/default.aspx) and also on Beating Bowel Cancer’s 
patient forum (htp://www.beatingbowelcancer.org/forum), 
asking bowel cancer patients for their general opinions and 
thoughts on the Trial. he feedback received was positive. he 
study was considered to be “worthwhile”.
Methods 
In accordance with the Protocol, a longitudinal cohort study 
was implemented between 1 April 2014 and 1 December 2014 
inclusive (the ‘Trial Period’). Data was collected at: 
•	 ‘T1” post-surgery and prior to chemotherapy treatment
•	 ‘T2” twelve to fourteen weeks ater irst scheduled chemotherapy 
treatment or 3 months post surgery (as appropriate)
•	 ‘T3” three months ater last scheduled chemotherapy 
treatment or approximately 6 months ater T2 (as appropriate).
Participants
During the Trial Period, a consecutive sample of patients 
between the ages of 18 and 65, diagnosed with resectable CRC 
under the care of the CRC team were invited to participate. 
Eligibility required patients to: 
a) Have undergone colorectal surgery
b) Not have distant metastases; and
c) Require adjuvant chemotherapy treatment or no post-
surgery treatment at all.
Areas of Focus Trial Objectives 
Implementation (the extent to 
which and the likelihood that the 
proposed multi-site study can be 
fully implemented in accordance 
with the Protocol1)
To what extent can the recruitment 
procedures be carried out as 
proposed? How willing are the 
clinical teams to facilitate and/or 
help recruit participants? 
Practicality (an exploration 
of the extent to which the 
Protocol may be delivered given 
available resources and time1) 
Capacity of staff and logistics. 
Acceptability (how will the 
individual recipients (both 
patients and clinicians) 
react to the procedures and 
assessments1) 
Acceptability of the data collection 
procedures and assessments to 
participants and clinicians? 
Practicality
Attrition rates and time needed to 
collect and analyse data 
1These are an adaptation of the deinitions of each area of focus 
provided by Bowen et al, 2009 
Table 1: Areas of Focus and Trial Objectives.
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Patients with prior exposure to chemotherapy and those with 
signiicant psychiatric or medical comorbidities, which might afect 
ability to participate in the Trail, were excluded. Patients could not 
enter the Trial if they were unable to read and speak English.
Measures
he measures used are detailed in the Protocol [6]. 
Trial sample size 
Extrapolating from the Protocol’s power calculation and 
assuming a total sample size of 156 participants (78 per group) to 
be recruited over 18 months, an average of eight to ten patients per 
calendar month would need to be consented into the Trial.
Procedure
Potential participants were identiied at the weekly CRC multi-
disciplinary team (MDT) meetings held by each Trust. 
Proposed recruitment procedures were as follows: 
•	 At the participant’s post-surgery follow-up appointment, 
typically three to six weeks ater surgery (‘OPA’), a member of 
the clinical team would introduce the researcher to the patient. 
•	 he researcher would then provide the patient with writen 
information about the Trial and answer questions raised. 
•	 he patient would be asked if they would be willing to 
be contacted by telephone within a few days to discuss 
participation in the Trial. Patients who agreed to participate 
were then given an appointment to meet with the researcher 
either at the hospital or at home. 
hose patients who did not wish to participate ater reviewing 
the information sheets were not contacted again. 
T1 assessments were planned to take place one to two 
weeks ater the OPA and prior to the patient’s irst scheduled 
chemotherapy appointment or at a parallel point in time for the 
surgery-only group. Eligible participants were to be consented into 
the Trial immediately prior to T1. he assessments for T1 were 
expected to take each participant approximately 2 hours and 30 
minutes to complete.
At the end of T1 participants were advised that they would be 
contacted again via telephone within approximately 10 to 12 weeks 
to arrange the meeting for T2. T2 would be scheduled for between 
12 and 14 weeks ater T1 or between cycle 6 and cycle 7 in the 
case of the chemotherapy treatment group and at a parallel point 
in time for the surgery only group.
he same process would be utilised for T3, with assessments 
carried out at participants’ homes at approximately 3 months ater 
the inal scheduled chemotherapy treatment, and at a similar point 
in time for the surgery-only participants. 
Based on the sample size calculation set out in the Protocol, the 
atrition rate could not exceed 22%.
Results
Recruitment procedures
he Trial indicated that procedures were quite similar at each 
Trust. At all Trusts the surgery-only follow-up appointments were 
more di cult to determine than the chemotherapy patients. 
Participant numbers
Recruiting from three Trusts (six hospital sites), atending 
all MDT's, surgical and chemotherapy clinics whilst also carrying 
out all assessments exceeded the single researcher’s capacity; 
indicating that recruitment would require additional staf. 
he surgery only control group proved more complex to recruit, 
as there were multiple surgeons at each hospital site making it 
di cult to identify all follow up OPAs. In addition eligible surgery-
only participants approached by the researcher oten refused 
participation as they asserted that they had completed treatment. 
Forty-two CRC patients across 3 Trusts were invited to 
participate during the Trial Period, twenty-three agreed and were 
consented; however ive changed their minds prior to completing 
T1. At the end of the Trial Period eighteen had completed T1 and 
eight T2. Seventeen of the eighteen remained in the Trial ater the 
Trial Period and completed T2. One patient withdrew ater T1 
due to the appearance of a new cancer lesion. he sample at T1 was 
made up from 38.8% males and 61.2% females with a mean age of 
59.7% years.
Fourteen of the eighteen participants (77.8%) were in the 
chemotherapy group. However, one participant was advised to 
start chemotherapy treatment several weeks ater completing 
T1 and another that started in the chemotherapy group stopped 
treatment ater three cycles but continued in the Trial. 
he rate of recruitment was approximately three per month 
once the recruitment procedures and working practices were 
established. his indicated that signiicantly more research capacity 
and sites were required as it would take approximately four years to 
recruit the 156 participants required with the current resource. 
Inclusion/exclusion criteria
Eligible participants were lower in number than expected in 
part due to the inclusion/exclusion criteria, age and also competing 
trials. Following ethics approval the age criterion was altered to 
have no upper age limit to increase recruitment. 
Methodology/Testing of data collection procedures and 
assessments
All participants completed the full Batery. Consequently the 
administration of the Batery was deemed appropriate.
A suitable testing environment was achieved by administering 
the Batery in a quiet space both at the hospitals and participants’ 
homes. 
At the completion of T1, participants were asked how they 
felt about the assessments. he comments made suggested that 
participants in both groups found the design, methods and 
procedures employed in the Trial appropriate. 
ID 1: “this was very enjoyable”
ID 14: “It took my mind of things, I enjoyed doing it”
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Attrition rates 
During the Trial Period, atrition at T2 was very low with 
only 1 participant withdrawing due to ill health. All participants 
who completed T1 expressed a desire to continue in the Trial. 
Continued participation in the Trial would suggest that the 
proposed multi-site study is worthwhile.
Conclusions 
he Trial provided evidence that the Protocol is feasible 
subject to increasing the number of researchers and collaborating 
sites both to improve recruitment rates and to prevent clashes with 
assessments. 
One possible solution to improving the rate of recruitment was 
implemented during the Trial Period, by removing the upper age 
limit for eligible participants. his has since made a diference in 
number of consented participants.
he number of patients consenting to the Trial and a very 
low atrition rate suggests that many CRC patients are willing to 
participate and that the Batery is feasible and well tolerated by 
patients. 
Another strength of the proposed Protocol evidenced during 
the Trial was the acceptability of the multi-site study to clinical 
teams demonstrated by requests of collaboration from two 
additional London based NHS Trusts. In addition, the Trial 
provides valuable information to other neuropsychologists 
interested in the cognitive efect of chemotherapy treatments in 
the form of a realistic plan. It also makes clear the requirement 
for suicient funding and resources. his could in turn allow for 
a large multi-institutional study across several English speaking 
cities and/or countries. All institutions could administer the same 
neuropsychological batery to a very large number of solid tumour 
cancer patients and pool all data as suggested by the International 
Cognition and Cancer Task Force [4].
One potential limitation of the proposed study however, is that 
the majority of patients had never heard of chemotherapy related 
cognitive changes, which may cause concern and/or priming 
efects. However, in the event that priming does occur it will do 
so in both the chemotherapy group and the surgery only group, so 
useful comparisons between the groups of any observed objective 
changes may still be made. In addition, any possible priming efects 
will not prohibit the researchers from being able to examine the 
impact of chemotherapy related subjective cognitive changes on 
the individuals’ quality of life.
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